ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use

American Journal of Gastroenterology

Volumn 103, Issue 11, 2008, Pages 2890-2907

  Bhatt, Deepak L ^a   Scheiman, James ^a   Abraham, Neena S ^a   Antman, Elliott M ^a   Chan, Francis K L ^a   Furberg, Curt D ^a   Johnson, David A ^a   Mahaffey, Kenneth W ^a   Quigley, Eamonn M ^a   Harrington, Robert A ^a   Bates, Eric R ^a   Bridges, Charles R ^a   Eisenberg, Mark J ^a   Ferrari, Victor A ^a   Hlatky, Mark A ^a   Kaul, Sanjay ^a   Lindner, Jonathan R ^a   Moliterno, David J ^a   Mukherjee, Debabrata ^a   Schofield, Richard S ^a   Rosenson, Robert S ^a   Stein, James H ^a   Weitz, Howard H ^a   Wesley, Deborah J ^a   more..

^a ACCF Task Force on Clinical Expert Consensus Documents ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BISMUTH SALICYLATE; CELECOXIB; CLARITHROMYCIN; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; LOW MOLECULAR WEIGHT HEPARIN; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROSTAGLANDIN; PROTON PUMP INHIBITOR; RANITIDINE; REVIPARIN; SUCRALFATE; TETRACYCLINE; TICLOPIDINE; WARFARIN;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; ARTHRITIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM INJURY; DRUG INHIBITION; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DUODENUM ULCER; FEVER; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NONHUMAN; PAIN; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; STOMACH HEMORRHAGE; STOMACH ULCER; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS; ULCEROGENESIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 55549124570     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02216.x     Document Type: Review

References (98)

1. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2008 51 : 210 47.
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007 50 : e1 157.
3. Grines CL, Bonow RO, Casey DE Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007 49 : 734 9.
4. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: Balancing the reduction in restenosis with the concern of late thrombosis. Lancet 2008 371 : 2134 43.
5. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation 2007 115 : 1634 42.
6. Bhatt DL. NSAIDS and the risk of myocardial infarction: Do they help or harm? Eur Heart J 2006 27 : 1635 6.
7. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005 112 : 759 70.
8. Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005 129 : 1171 8.
9. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995 40 : 1345 50.
10. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006 101 : 2128 38.
11. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998 41 : 778 99.
12. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996 25 : 279 98.
13. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: Epidemiology, prevention and treatment. Curr Med Res Opin 2007 23 : 163 73.
14. Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000 119 : 706 14.
15. Cox ER, Frisse M, Behm A, et al. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med 2004 164 : 1243 6.
16. Abraham NS, El-Serag HB, Hartman C, et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007 25 : 913 24.
17. Ma L, Elliott SN, Cirino G, et al. Platelets modulate gastric ulcer healing: Role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA 2001 98 : 6470 5.
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 21 : 60 5.
19. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000 343 : 1520 8.
20. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988 109 : 359 63.
21. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991 114 : 257 63.
22. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995 141 : 539 45.
23. Hawkey CJ, Talley NJ, Scheiman JM, et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: The NASA2 and SPACE2 studies. Arthritis Res Ther 2007 9 : R17.
24. Ofman JJ, MacLean CH, Straus WL, et al. A meta-analysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002 29 : 804 12.
25. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999 56 : 18 24.
26. Abraham NS, Castillo DL, Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther 2008 28 : 97 106.
27. Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal anti-inflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004 50 : 2433 40.
28. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based case-control study. BMJ 2006 333 : 726.
29. Johnson DA. Upper GI risks of NSAIDs and antiplatelet agents: Key issues for the cardiologist. Rev Cardiovasc Med 2005 6 (Suppl 4 S15 22.
30. Abraham NS, Hartman C, Castillo D, et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 2008 103 : 323 32.
31. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000 343 : 834 9.
32. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007 369 : 1580 1.
33. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002 106 : 388 91.
34. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007 115 : 1481 501.
35. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 136 : 161 72.
36. Chan FK, Graham DY. Review article: Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004 19 : 1051 61.
37. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995 310 : 827 30.
38. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005 22 : 795 801.
39. de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001 1 : 1.
40. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996 348 : 1413 6.
41. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006 119 : 624 38.
42. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006 4 : 22.
43. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000 95 : 2218 24.
44. Wilcox CM, Shalek KA, Cotsonis G. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med 1994 154 : 42 6.
45. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ 2000 321 : 1183 7.
46. Laine L, McQuaid K. Bleeding complications related to aspirin dose. Am J Cardiol 2005 96 : 1035 6.
47. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005 95 : 1218 22.
48. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 324 : 71 86.
49. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003 108 : 1682 7.
50. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. Br J Clin Pharmacol 2001 52 : 563 71.
51. Berger JS, Stebbins A, Granger CB, et al. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 2008 117 : 192 9.
52. King SB III., Smith SC Jr., Hirshfeld JW Jr., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2007 Writing Group to Review New Evidence and Update the 2005 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention). J Am Coll Cardiol 2008 51 : 172 209.
53. Eikelboom JW, Hirsh J. Combined antiplatelet and anticoagulant therapy: Clinical benefits and risks. J Thromb Haemost. 2007 5 (Suppl 1 255 63.
54. Lanas A, Serrano P, Bajador E, et al. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol 2003 15 : 173 8.
55. Taha AS, Angerson WJ, Knill-Jones RP, et al. Upper gastrointestinal haemorrhage associated with low-dose aspirin and antithrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2005 22 : 285 9.
56. Younossi ZM, Strum WB, Schatz RA, et al. Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Dig Dis Sci 1997 42 : 79 82.
57. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials. BMJ 1996 313 : 652 9.
58. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996 347 : 561 8.
59. Yusuf S, Mehta SR, Xie C, et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005 293 : 427 35.
60. Andreotti F, Testa L, Biondi-Zoccai GG, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006 27 : 519 26.
61. Hirsh J, Guyatt G, Albers GW, et al. Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 133 : 71 109.
62. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 348 : 1329 39.
63. Bhatt DL, Hirsch AT, Ringleb PA, et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000 140 : 67 73.
64. Gluckman TJ, Baranowski B, Ashen MD, et al. A practical and evidence-based approach to cardiovascular disease risk reduction. Arch Intern Med 2004 164 : 1490 1500.
65. Grines CL, Bonow RO, Casey DE Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007 115 : 813 8.
66. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494 502.
67. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004 364 : 331 7.
68. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 354 : 1706 17.
69. Bhatt DL. Intensifying platelet inhibition - navigating between Scylla and Charybdis. N Engl J Med 2007 357 : 2078 81.
70. Bavry AA, Bhatt DL. Drug-eluting stents: Dual antiplatelet therapy for every survivor?. Circulation 2007 116 : 696 9.
71. Sheikh RA, Romano PS, Prindiville TP, et al. Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal antiinflammatory drugs and controls. J Clin Gastroenterol 2002 34 : 529 32.
72. Fork FT, Lafolie P, Toth E, et al. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers: A gastroscopic study. Scand J Gastroenterol 2000 35 : 464 9.
73. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006 55 : 1731 8.
74. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005 352 : 238 44.
75. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006 4 : 860 5.
76. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007 102 : 507 15.
77. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007 357 : 217 27.
78. Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006 18 : 162 4.
79. Donnelly MT, Goddard AF, Filipowicz B, et al. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000 14 : 529 34.
80. Goldstein JL, Huang B, Amer F, et al. Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: Results of a post HOC subanalysis. Clin Ther 2004 26 : 1637 43.
81. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 123 : 241 9.
82. Kitchingman GK, Prichard PJ, Daneshmend TK, et al. Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine. Br J Clin Pharmacol 1989 28 : 581 5.
83. Cole AT, Brundell S, Hudson N, et al. Ranitidine: Differential effects on gastric bleeding and mucosal damage induced by aspirin. Aliment Pharmacol Ther 1992 6 : 707 15.
84. Chin MW, Yong G, Bulsara MK, et al. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: A case-control study. Am J Gastroenterol 2007 102 : 2411 6.
85. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002 346 : 2033 8.
86. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001 344 : 967 73.
87. Lanas A, Rodrigo L, Marquez JL, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 2003 38 : 693 700.
88. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006 101 : 701 10.
89. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008 51 : 256 60.
90. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008 51 : 1925 34.
91. Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002 16 : 779 86.
92. Stack WA, Atherton JC, Hawkey GM, et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002 16 : 497 506.
93. Chan FK. Long-term incidence of ulcer bleeding with low-dose aspiring after eradication of H. pylori: A 4-year prospective cohort study (abstr). Gastroenterology 2005 128 : A133.
94. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 102 : 1808 25.
95. Dorward S, Sreedharan A, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2006 CD005415.
96. Green FW Jr., Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation: A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978 74 : 38 43.
97. Sung J, Lau J, Ching J, et al. Can aspirin be reintroduced with PPI inhibitor INFUSION after endoscopic hemostatis: A double-blinded randomized controlled trial (abstr). Gastroenterology 2008 130 : A44.
98. Eisen GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002 55 : 775 9.